On March 1, 2025 Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and imaging drugs, reported completion of a Series A2 funding round, securing $10.5M to advance early stage development for its lead programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are building a strong body of evidence that our zwitterionic platform has broad applicability in the oncology landscape and the funding we’ve attracted from strong investment partners demonstrates the enthusiasm for this opportunity," said John Brimacombe, Curadel President. "Building upon strong proof of concept data in imaging drugs, we are now focused on applying the power of zwitterionicity to deliver profound improvements in the outcomes associated with TATs, initially for rare cancers."

The most recent funding aims to support critical validating steps for the platform and the lead candidate CPI-003, including proof of synthesis studies, preclinical development and regulatory preparations. Work continues on ZW800-1, Curadel’s imaging drug, which is under evaluation in a pivotal trial led by a Tier 1 medical device company.

(Press release, Curadel Pharma, MAR 1, 2025, View Source [SID1234662084]).